Suppr超能文献

亚临床甲状腺功能减退症中新兴的心血管危险因素:甲状腺功能恢复正常后无变化。

Emerging cardiovascular risk factors in subclinical hypothyroidism: lack of change after restoration of euthyroidism.

作者信息

Pérez A, Cubero J M, Sucunza N, Ortega E, Arcelús R, Rodriguez-Espinosa J, Ordoñez-Llanos J, Blanco-Vaca F

机构信息

Serveis d'Endocrinologia, Bioquímica i Institut de Recerca, Hospital Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, 08025 Barcelona, Spain.

出版信息

Metabolism. 2004 Nov;53(11):1512-5. doi: 10.1016/j.metabol.2004.05.016.

Abstract

Subclinical hypothyroidism (SH) is a frequent condition that may be associated with increased cardiovascular risk. There is current interest in determining the effect, if any, of substitutive therapy with l-thyroxine (L-T4) on cardiovascular risk factors in SH and, particularly, on those associated with emerging cardiovacular risk, such as apolipoprotein (apo) B, lipoprotein (Lp) (a), total homocysteine (t-Hcy), and C-reactive protein (CRP). Thus, the aim of this study was to assess the impact of euthyroidism restoration on these emerging risk factors in SH. Forty-two patients diagnosed with SH were consecutively recruited before treatment. These patients were treated with L-T4 for 3 to 6 months with the dose necessary to restore euthyroidism. Lp(a), fasting and postmethionine (n = 28) t-Hcy, and CRP did not change with substitutive therapy, regardless of the respective baseline values, and the decrease in apo B paralleled that of low-density lipoprotein (LDL) cholesterol. Similarly, no treatment effect was observed on homocysteine or CRP in patients with thyrotropin-stimulating hormone (TSH) >10 mIU/L. Monitoring of emerging risk factors did not offer additional arguments for treating patients with SH and, thus, is not justified in their clinical management.

摘要

亚临床甲状腺功能减退(SH)是一种常见病症,可能与心血管风险增加相关。目前人们关注左甲状腺素(L-T4)替代疗法对SH患者心血管危险因素的影响,尤其是对那些与新出现的心血管风险相关的因素,如载脂蛋白(apo)B、脂蛋白(Lp)(a)、总同型半胱氨酸(t-Hcy)和C反应蛋白(CRP)的影响。因此,本研究的目的是评估甲状腺功能正常化对SH患者这些新出现的危险因素的影响。42例确诊为SH的患者在治疗前被连续招募。这些患者接受L-T4治疗3至6个月,使用恢复甲状腺功能正常所需的剂量。无论各自的基线值如何,Lp(a)、空腹和蛋氨酸负荷后(n = 28)的t-Hcy以及CRP在替代治疗后均未改变,apo B的下降与低密度脂蛋白(LDL)胆固醇的下降平行。同样,促甲状腺激素(TSH)>10 mIU/L的患者在同型半胱氨酸或CRP方面未观察到治疗效果。监测新出现的危险因素并不能为治疗SH患者提供额外的依据,因此在其临床管理中没有必要。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验